Edition:
United Kingdom

People: Piramal Enterprises Ltd (PIRA.NS)

PIRA.NS on National Stock Exchange of India

1,782.80INR
11:29am BST
Change (% chg)

Rs2.20 (+0.12%)
Prev Close
Rs1,780.60
Open
Rs1,788.00
Day's High
Rs1,799.00
Day's Low
Rs1,757.00
Volume
642,151
Avg. Vol
1,051,750
52-wk High
Rs3,307.95
52-wk Low
Rs1,652.35

Rajadnye, Kedar 

Mr. Kedar Rajadnye is Chief Operating Officer - Consumer Products of the company. He is the COO of the Consumer Products business of Piramal Enterprises, one of the fastest growing self-care businesses in India. He is also responsible for the IT function of the Piramal Group. He joined the Piramal Group in 2004 to head a portfolio of domestic pharmaceutical business. Since 2008, he has been responsible for the Consumer Products division, which is consistently growing faster than the market. Over the years in the Indian OTC market, it has moved up from 40th rank in 2007 to the current 7th rank. Under his stewardship, the business has built one of the strongest Chemist distribution capabilities in India. He has played an influential role in building strong OTC brands such as Lacto Calamine, Saridon, Ipill, Tetmosol and Caladryl. Most of these brands are ranked either no.1 or no.2 in their respective categories. He was instrumental in acquisitions of Little’s, Naturolax, Lactobacilus and other brands last year. Prior to joining the Group, Mr. Rajadnye has worked at Hindustan Unilever for eight years in the sales and marketing division. He is an alumnus of Jamnalal Bajaj Institute of Management Studies and has also completed the Executive Development programme from the Harvard Business School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ajay Piramal

112,489,000

Swati Piramal

50,451,400

Vivek Valsaraj

14,642,000

Peter DeYoung

--

Jonathan Sandler

--

Vivek Sharma

--
As Of  31 Mar 2018